BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ideon - ECPv6.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ideon
X-ORIGINAL-URL:https://ideon.se
X-WR-CALDESC:Events for ideon
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20220914T143000
DTEND;TZID=Europe/Stockholm:20220914T180000
DTSTAMP:20260617T190405
CREATED:20220824T121657Z
LAST-MODIFIED:20240718T214641Z
UID:375389-1663165800-1663178400@ideon.se
SUMMARY:MVA MEDTECH NETWORK MEETING
DESCRIPTION:DRUG DEVICE COMBINATION PRODUCTS AND SUBSTANCE BASED MEDICAL DEVICESMedicon Valley Alliance\, together with member company Innokas Medical\, have the pleasure to invite you to the Medicon Valley Alliance MedTech Network meeting\, on the 14th of September\, focusing on drug device combination products and substance based medical devices.The market for drug device combination products is growing and it is anticipated that up to one in three medical products in development is a combination of a drug/substance and a MedTech product. Drivers for the growth in combination products is the rise of patients suffering from chronic diseases such as diabetes\, cancer\, and respiratory problems as well as growth in the home-based health care market and technological advancements.When searching for the correct regulatory approval in the EU the primary mode of action (PMOA) will define the regulatory path for your products. For example\, if the action of your medicinal substance is ancillary\, then your product is regulated as a medical device under MDR\, on the other hand if the product is mainly of the medicinal substance the product will be regulated as a medicinal product.  A substance with therapeutic effect can be either a medicinal product/drug or a medical device\, depending on its primary mechanism of action.Developing this type of products are associated with a high level of complexity. For combination products  you need to navigate two of the most intensely regulated pathways in one go: for pharmaceuticals and medical devices. The re-classification of substance-based medical devices according to MDR means a more extensive risk assessment involving scientific evidence of PMOA.In this MVA MedTech Network meeting we would like to invite you to hear from experts in the area of developing drug device combination products and substance based medical devices as well as hearing from companies sharing their experiences\, challenges and solutions.  \nClick here for more information and registration»\n If you are interested in sharing your company’s approach and experiences with drug device combination products and/or substance based medical devices and to speak at the meeting on the 14th of September\, please reach out to Sofia Norås\, sn@mva.org.
URL:https://ideon.se/event/mva-medtech-network-meeting/
ATTACH;FMTTYPE=image/jpeg:https://ideon.se/wp-content/uploads/2024/07/220914-medtech-network-banner-1080.jpg
END:VEVENT
END:VCALENDAR